Efficacy, safety, and cost-effectiveness of pegylated PEG-rhg-CSF in pediatric patients receiving high-intensity chemotherapy: results from a phase II study

• প্রধান লেখক: Junting Huang (লেখক), Jia Zhu (লেখক), Lian Jiang (লেখক), Jiaqian Xu (লেখক), Xiheng Lin (লেখক), Jian Chang (লেখক), Xiaohong Zhang (লেখক), Suying Lu (লেখক), Feifei Sun (লেখক), Juan Wang (লেখক), Yi Que (লেখক), Zhonglv Ye (লেখক), Lihua Yang (লেখক), Xiuli Yuan (লেখক), Weisong Cai (লেখক), Chuan Tian (লেখক), Yanpeng Wu (লেখক), Xiangling He (লেখক), Yan-Lai Tang (লেখক), Yizhuo Zhang (লেখক)
• বিন্যাস: গ্রন্থ
• প্রকাশিত: Frontiers Media S.A., 2024-07-01T00:00:00Z.
• বিষয়গুলি: article
• অনলাইন ব্যবহার করুন: Connect to this object online.

BackgroundHigh-intensity chemotherapy can cause life-threatening complications in pediatric patients. Therefore, this study investigated safety and efficacy of long-acting pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF; Jinyouli®) in children undergoing high-intensity...